Highlights
- •80.2% of adults without overt CVD had LDL-C ≥3 mmol/l.
- •Severe hypercholesterolaemia (SH) was present in 3.2% of middle-aged Lithuanians.
- •Decreasing prevalence of SH was observed during 2009–2016 in Lithuania.
- •Likely phenotypic familial hypercholesterolaemia was found in 1.5% of middle-aged adults.
Abstract
Background and aims
Cardiovascular disease (CVD) is a major cause of premature death in Lithuania where
abnormal lipid levels are very common among middle-aged adults. The aim of this study
was to evaluate lipid profile in middle-aged Lithuanians and perform population-based
severe hypercholesterolaemia (SH) screening.
Methods
This study included men aged 40–54 and women aged 50–64 years without overt CVD, participating
in the Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme during
the period 2009–2016. Lipidograms of 92,373 adults (58.4% women and 41.6% men) included
in the database were analysed and screening for SH was performed.
Results
The mean levels of total cholesterol, LDL cholesterol (LDL-C) and triglycerides (TG)
among participants were 6.08 mmol/l, 3.87 mmol/l, and 1.59 mmol/l, respectively. Any
type of dyslipidaemia was present in 89.7%, and severe dyslipidaemia in 13.4% of the
study population.
80.2% of adults without overt CVD had LDL-C ≥3 mmol/l. SH (LDL-C ≥6 mmol/l) was detected
in 3.2% of study participants. Prevalence of SH decreased from 2.91% to 2.82% during
the period 2009–2016 (p for trend = 0.003). LDL-C ≥6.5 mmol/l was observed in 1.5% of subjects while both
LDL-C ≥6.5 mmol/l, and TG ≤ 1.7 mmol/l was found in 0.6% of subjects.
Conclusions
SH was present in 3.2% of the middle-aged population without overt CVD. Slightly decreasing
prevalence of SH was observed during the period 2009–2016 in Lithuania. Likely phenotypic
familial hypercholesterolaemia was observed in 1.5% of middle-aged Lithuanians. Further
clinical and genetic evaluation of people with SH is needed to detect familial forms
of SH.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study.Rev. Esp. Cardiol. 2011; 64: 286-294
- Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.BMC Cardiovasc. Disord. 2017; 17: 160
- Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium.Circulation. 2006; 113: 647-656
- Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines.J. Am. Coll. Cardiol. 2004; 44: 720-732
- Prevalence of Cardiovascular Risk Factors in Lithuanian Middle-aged Subjects Participating in the Primary Prevention Program, Analysis of the Period 2009-2012.Blood Press, 2015: 41-47 (vol. 24(1))
- 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and European atherosclerosis society (EAS).Eur. Heart J. 2016 Aug 27; (pii: ehw272. [Epub ahead of print])
- Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Nat. Rev. Endocrinol. 2016; 12: 467-484
- Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.J. Am. Coll. Cardiol. 2016; 67: 2578-2589
- Opportunistic screening for familial hypercholesterolaemia via a community laboratory.Ann. Clin. Biochem. 2012; 49: 534-537
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.Eur. Heart J. 2013; 34: 3478-3490a
- Screening for familial hypercholesterolaemia.Pathology. 2012; 44: 122-128
- Design of the familial hypercholesterolaemia australasia network registry: creating opportunities for greater international collaboration.J. Atherosclerosis Thromb. 2017; 24: 1075-1084
- Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme - rationale and design.Seminars in Cardiovascular Medicine. 2012; 18: 3
- Familial Hypercholesterolaemia (FH): Report of a Second WHO Consultation.World Health Organization, Geneva1999
- Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - the EURIKA Study.BMC Publ. Health. 2011; 11: 704
- Prevalence of lipid abnormalities in the United States: the national health and nutrition examination survey 2003-2006.J Clin Lipidol. 2012; 6: 325-330
- Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report.Circulation. 2002; 106: 3143-3421
- The prevalence, awareness, treatment and control of dyslipidemia among adults in China.Atherosclerosis. 2016; 248: 2-9
- Dyslipidemia in primary care- prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).Cardiovasc. Diabetol. 2008; 7: 31
- Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the european society of cardiology european action on secondary and primary prevention by intervention to reduce events (EUROASPIRE) IV cross-sectional survey in 14 european regions.Eur J Prev Cardiol. 2016; 23: 2007-2018
- Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.Circulation. 2011; 123: 2292-2333
- Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.Clin. Res. Cardiol. 2010; 99: 723-733
- Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).Can. J. Cardiol. 2010; 26: e330-e335
- Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).Rev. Port. Cardiol. 2011; 30: 47-63
Article Info
Publication History
Accepted:
June 7,
2018
Received in revised form:
May 29,
2018
Received:
March 31,
2018
Identification
Copyright
© 2018 Elsevier B.V. All rights reserved.
